Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Kimberley Allen-PhilbeyStefania De TraneAmy MacDougallAshok AdamsLucia BianchiThomas CampionGavin GiovannoniSharmilee GnanapavanDavid W HoldenMonica MartaJoela MathewsBenjamin P TurnerDavid BakerKlaus SchmiererPublished in: Therapeutic advances in neurological disorders (2023)
Re-emerging disease activity was associated with baseline MRI activity and low dose second course of SClad.